Open Book Extracts (OBE) and Case Western Reserve University School of Medicine, one of the country's leading private research institutions, have entered into an agreement to explore the mechanistic effects of cannabinoids on brain cell functions.
Under the terms of the agreement, Case Western Reserve is being provided access to pure cannabinoid materials from OBE, including CBD, CBG, CBN, CBC, THCV, and CBDV isolates and custom formulations. Specifically, Case Western Reserve scientists will assess the potential of pure cannabinoid isolates and precise ratios of specific cannabinoids in formulations, to understand the impact of cannabinoids on brain cell functions, with a focus on neuroinflammation.
Paul Tesar, PhD, the Dr. Donald and Ruth Weber Goodman Professor of Innovative Therapeutics in the Department of Genetics and Genome Sciences at the Case Western Reserve School of Medicine, is the principal investigator for the study. His laboratory has pioneered new regenerative approaches to treat nervous-system disorders including multiple sclerosis, neuromyelitis optica, pediatric leukodystrophies, cerebral palsy, and brain cancer. Tesar is also co-founder of Convelo Therapeutics, a company developing medicines to regenerate myelin around nerve cells and restore function to patients with neurological disorders.
"There is a salient need for rigorous research related to the use of cannabinoids," Tesar said. "Together, OBE and Case Western Reserve are advancing that research, and we look forward to evaluating the safety and efficacy of cannabinoid therapies via scientific rigor. OBE's focus on the innovation, quality, safety and consistency of its products makes them an ideal collaborator for our research program."
Case Western Reserve will undertake preclinical investigation of numerous therapeutic compounds selected from OBE's extensive library of proprietary cannabinoid analogs. Using its validated cellular assays and assessment criteria, Case Western Reserve will also explore the therapeutic potential of specific compounds in selected disease models, including an evaluation of the impact of compounds on neuroinflammation.
Powered by their cGMP operations in North Carolina and a team of world class scientists, OBE offers one of the largest portfolios of cannabinoid isolates at purity, including CBD, CBG, CBN, CBC. THCV, all at greater than 99 percent purity.
In addition to cannabinoid isolates, OBE also offers custom-blend THC-free broad-spectrum distillates that can be tailored to meet customer specifications, water-soluble powders and liquids, and a portfolio of finished products including edibles, soft gels, tablets, tinctures, and topical products. The company’s in-house formulation team can also support product development for private label manufacturing.
Having recently completed a round of financing to accelerate key strategic initiatives, OBE is leveraging it's real world efficacy feedback to inform clinical studies, IP development, and research such as the investigation with Case Western Reserve to hone in on therapeutically-targeted cannabinoid solutions.
"OBE is honored to work with Case Western Reserve University School of Medicine,” said OBE CEO Dave Neundorfer. “Their position as one of the leading global medical research institutions will assist us in advancing our understanding of the benefits of cannabinoids in treating a wide spectrum of diseases and conditions. OBE is pioneering the development of cannabinoid therapies through strategic partnerships with leading institutions such as Case Western Reserve. We believe that research is essential to optimize the targeted benefits of cannabinoids, allowing us to develop new and proven products for consumers around the world."